We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.95%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.85B
AUM Growth
-$38.7M
Cap. Flow
-$602M
Cap. Flow %
-21.14%
Top 10 Hldgs %
27.89%
Holding
132
New
16
Increased
23
Reduced
29
Closed
17

Top Buys

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$55.3M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$48.6M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$41.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$27.9M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$27.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$93.4M
2
DXCM icon
DexCom
DXCM
+$41M
3
DVA icon
DaVita
DVA
+$32.1M
4
GSK icon
GSK
GSK
+$31.6M
5
VTRS icon
Viatris
VTRS
+$31.6M

Sector Composition

Rank Sector Weight
1 Healthcare 73.94%
2 Financials 2.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAC
51
DELISTED
AAC Holdings
AAC
$17.4M 0.61%
1,853,998
– –
ARNA
52
DELISTED
Arena Pharmaceuticals Inc
ARNA
$17.4M 0.61%
398,194
-299,000
-43% -$12.9M
OXFD
53
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$16.9M 0.59%
1,311,000
-133,000
-9% -$1.8M
AVDL
54
DELISTED
Avadel Pharmaceuticals
AVDL
$16.7M 0.59%
2,722,241
-1,066,299
-28% -$7.48M
CTMX icon
55
CytomX Therapeutics
CTMX
$788M
$16.7M 0.59%
729,948
-23,374
-3% -$597K
MOH icon
56
Molina Healthcare
MOH
$11.7B
$16.5M 0.58%
168,000
– –
BHVN
57
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$15.7M 0.55%
398,000
-471,000
-54% -$14.9M
DXCM icon
58
DexCom
DXCM
$29.6B
$15.7M 0.55%
660,700
-1,935,300
-75% -$41M
LKFT
59
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$15.2M 0.53%
165,000
+35,000
+27% +$3.4M
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$35.7B
$14.4M 0.51%
146,000
– –
NVTA
61
DELISTED
Invitae Corporation
NVTA
$14M 0.49%
1,901,788
– –
ZBH icon
62
Zimmer Biomet
ZBH
$17.6B
$13.5M 0.47%
124,630
– –
SYBX
63
DELISTED
Synlogic
SYBX
$13.4M 0.47%
91,010
– –
SYRS
64
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$13M 0.46%
126,895
– –
ARDX icon
65
Ardelyx
ARDX
$1.28B
$12.9M 0.45%
3,491,922
+889,189
+34% +$4.13M
SIEN
66
DELISTED
Sientra, Inc.
SIEN
$12.7M 0.44%
64,910
+53,910
+490% +$8.55M
GTHX
67
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$12.5M 0.44%
287,000
-86,000
-23% -$3.68M
FTSV
68
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$9.6M 0.34%
+600,000
New +$9.31M
PRTA icon
69
Prothena Corp
PRTA
$453M
$9.16M 0.32%
+628,262
New +$12.4M
IVTY
70
DELISTED
Invuity, Inc
IVTY
$9.11M 0.32%
2,336,889
– –
WMGI
71
DELISTED
Wright Medical Group Inc
WMGI
$9.07M 0.32%
349,539
-284,461
-45% -$6.5M
RGNX icon
72
Regenxbio
RGNX
$534M
$8.97M 0.32%
125,000
-131,300
-51% -$6.27M
TBIO
73
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$8.22M 0.29%
+650,000
New +$7.86M
ECOR icon
74
electroCore
ECOR
$48.8M
$7.02M 0.25%
+28,362
New +$7.71M
ALPN
75
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.91M 0.24%
913,100
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2018 Portfolio in Review

As of Q2 2018, Deerfield Management held 132 positions worth $2.85B, down 1.3% from $2.89B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Deerfield Management withdrew a net $602M in Q2 2018, closing 17 positions and reducing 29 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $93.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Portola Pharmaceuticals, Inc. worth $54.6M.

  • Deerfield Management's largest Q2 2018 buy was Portola Pharmaceuticals, Inc.: 1,446,633 shares worth $54.6M.
  • Deerfield Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2018, an estimated $41.7M increase.
  • Deerfield Management's biggest Q2 2018 reduction was DexCom, cutting an estimated $41M.
  • Deerfield Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $93.4M.
  • Deerfield Management's ten largest holdings make up 28% of its $2.85B portfolio in Q2 2018.
  • Deerfield Management opened 16 new positions and closed 17 in Q2 2018.
  • Deerfield Management's portfolio value fell 1.3% quarter-over-quarter to $2.85B.

Based on Deerfield Management's 13F filing for Q2 2018, filed 14 Aug 2018.